Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Leukoc Biol ; 114(6): 604-614, 2023 11 24.
Artículo en Inglés | MEDLINE | ID: mdl-37647586

RESUMEN

Bronchopulmonary dysplasia, a common complication of premature infants, is mainly characterized by blocked alveolarization. Proverbially, the injury of alveolar type II epithelial cells is regarded as the pathologic basis of occurrence and development of bronchopulmonary dysplasia. In the case of alveolar epithelial damage, alveolar type II epithelial cells can also differentiate to alveolar type I epithelial cells as progenitor cells. During bronchopulmonary dysplasia, the differentiation of alveolar type II epithelial cells becomes abnormal. Group 2 innate lymphoid cells can produce type 2 cytokines in response to a variety of stimuli, including the epithelial cytokines IL-25, IL-33, and thymic stromal lymphopoietin. Previous studies have shown that group 2 innate lymphoid cells can inhibit the alveolarization process of bronchopulmonary dysplasia by secreting IL-13. However, whether group 2 innate lymphoid cells can affect the differentiation of alveolar type II epithelial cells in the pathologic process of bronchopulmonary dysplasia remains unclear. In this study, we have shown that IL-13 secreted by group 2 innate lymphoid cells increased during bronchopulmonary dysplasia, which was related to the release of large amounts of IL-33 by impaired alveolar type II epithelial cells. This led to abnormal differentiation of alveolar type II epithelial cells, reduced differentiation to alveolar type I epithelial cells, and increased transdifferentiation to mesenchymal cells through the epithelial-mesenchymal transition. Taken together, our study provides a complementary understanding of the development of bronchopulmonary dysplasia and highlights a novel immune mechanism in the pathogenesis of bronchopulmonary dysplasia.


Asunto(s)
Displasia Broncopulmonar , Recién Nacido , Ratones , Animales , Humanos , Displasia Broncopulmonar/etiología , Displasia Broncopulmonar/patología , Interleucina-33 , Inmunidad Innata , Interleucina-13 , Linfocitos/patología , Células Epiteliales Alveolares/patología , Diferenciación Celular , Citocinas
2.
Acta Pharmacol Sin ; 37(5): 629-36, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26997568

RESUMEN

AIM: We previously proven that carbocisteine, a conventional mucolytic drug, remarkably reduced the rate of acute exacerbations and improved the quality of life in the patients with chronic obstructive pulmonary disease. In this study we investigated the mechanisms underlying the anti-inflammatory effects of carbocisteine in human alveolar epithelial cells in vitro. METHODS: Human lung adenocarcinoma cell line A549 was treated with TNF-α (10 ng/mL). Carbocisteine was administered either 24 h prior to or after TNF-α exposure. The cytokine release and expression were measured using ELISA and qRT-PCR. Activation of NF-κB was analyzed with Western blotting, immunofluorescence assay and luciferase reporter gene assay. The expression of ERK1/2 MAPK signaling proteins was assessed with Western blotting. RESULTS: Carbocisteine (10, 100, 1000 µmol/L), administered either before or after TNF-α exposure, dose-dependently suppressed TNF-α-induced inflammation in A549 cells, as evidenced by diminished release of IL-6 and IL-8, and diminished mRNA expression of IL-6, IL-8, TNF-α, MCP-1 and MIP-1ß. Furthermore, pretreatment with carbocisteine significantly decreased TNF-α-induced phosphorylation of NF-κB p65 and ERK1/2 MAPK, and inhibited the nuclear translocation of p65 subunit in A549 cells. In an NF-κB luciferase reporter system, pretreatment with carbocisteine dose-dependently inhibited TNF-α-induced transcriptional activity of NF-κB. CONCLUSION: Carbocisteine effectively suppresses TNF-α-induced inflammation in A549 cells via suppressing NF-κB and ERK1/2 MAPK signaling pathways.


Asunto(s)
Células Epiteliales Alveolares/efectos de los fármacos , Carbocisteína/farmacología , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , FN-kappa B/metabolismo , Factor de Necrosis Tumoral alfa/farmacología , Células A549 , Células Epiteliales Alveolares/metabolismo , Citocinas/metabolismo , Células HEK293 , Humanos , Inflamación/metabolismo , Transducción de Señal , Factor de Necrosis Tumoral alfa/metabolismo
3.
Int Immunopharmacol ; 24(2): 306-313, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25533503

RESUMEN

Carbocisteine is a mucolytic drug with anti-oxidative effect, we had previously proved that carbocisteine remarkably reduced the rate of acute exacerbations and improved the quality of life in patients with chronic obstructive pulmonary disease (COPD), however, very little is known about its mechanisms. In this study, we aimed to investigate the anti-inflammatory effects of carbocisteine against hydrogen peroxide (H2O2). A549 cells were cultured in vitro and treated with H2O2 as damaged cell models, carbocisteine was administered 24h prior to or after H2O2 exposure, and the protective effects of carbocisteine were determined by MTT, qRT-PCR, ELISA, western blot and immunofluorescence assays. The results showed that carbocisteine could increase cell viability and decrease LDH, IL-6 and IL-8 levels in the supernatant. Additionally, carbocisteine decreased IL-6, IL-8, TNF-α, IP-10 and MIP-1ß mRNA in a dose-dependent manner. Moreover, carbocisteine could attenuate phosphorylation of NF-κB p65 and ERK1/2 and inhibit the nuclear translocation of pNF-κB p65 induced by H2O2. In conclusion, carbocisteine inhibited H2O2-induced inflammatory injury in A549 cells, NF-κB and ERK1/2 MAPK were the target pathways.


Asunto(s)
Antiinflamatorios/farmacología , Carbocisteína/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Citocinas/genética , Citocinas/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Peróxido de Hidrógeno , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , FN-kappa B/metabolismo
4.
Zhong Yao Cai ; 31(8): 1216-9, 2008 Aug.
Artículo en Chino | MEDLINE | ID: mdl-19112906

RESUMEN

OBJECTIVE: To investigate the best extraction process of Sambucus chinensis against hepatitis and research on its active part. METHODS: We studied the protective effects of different extracts of Sambucus chinensis distilled by different extraction process on mice acute hepatic injury induced by CCl4, and searched for the active part of Sambucus chinensis against hepatitis from the best extract by extraction with different solvent and purification with macroporous adsorption resin, then studied their protective effects on mice acute hepatic injury induced by CCl4. RESULTS: The extraction of Sambucus chinensis by 75% alcohol showed very significantly protective effects on mice acute hepatic injury induced by CCl4 and the effects were better than that of other extraction process. The extraction eluted by 30% alcohol after purification with macroporous adsorption resin and extracted by EtOAc in the extraction of Sambucus chinensis by 75% alcohol all showed significantly protective effects on mice acute hepatic injury induced by CCl4, and the effects of the extraction eluted by 30% alcohol after purification with macroporous adsoption resin were better than extraction with EtOAc. CONCLUSIONS: The best extraction solvent is 75% alcohol. The active part of Sambucus chinensis against hepatitis is the extraction eluted by 30% alcohol after purification with macroporous adsorption resin and extraction with EtOAc.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Fitoterapia , Sambucus/química , Tecnología Farmacéutica/métodos , Alanina Transaminasa/sangre , Animales , Aspartato Aminotransferasas/sangre , Intoxicación por Tetracloruro de Carbono , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/aislamiento & purificación , Medicamentos Herbarios Chinos/farmacología , Etanol/química , Masculino , Ratones , Plantas Medicinales/química , Resinas Sintéticas/química , Solventes/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...